Beam Therapeutics (BEAM) is up 10.8%, or $2.91 to $30.02.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
- Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
- Beam Therapeutics price target raised to $68 from $64 at Citi
- Clear Street sees buying opportunity for Beam Therapeutics after study update
- Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target